Nenad Grmusa, joined DEM Bio as Chief Executive Officer in September 2022. Prior to joining DEM Bio, Mr. Grmusa led the R&D Strategy and External Innovation group at Takeda. In this role, he oversaw all external research and development activities including strategic venture investments, academic alliances, R&D collaborations, and spinouts. He was also responsible for R&D Finance and Portfolio Strategy, innovative R&D business and venture investment models, and divestiture strategies for non-core assets.

Previously, Mr. Grmusa served as Head, Center for External Innovation and R&D Portfolio & Investment Strategy at Takeda, where he supported the Head of R&D in managing Takeda’s diverse pipeline from early discovery to commercial life cycle management. Mr. Grmusa has 20 years of experience in R&D finance, financial planning and analysis, and pharmaceutical portfolio management.

Prior to joining Takeda, Mr. Grmusa spent 10 years with Millennium Pharmaceuticals, Inc. in various financial planning and analytical roles with increasing responsibilities. While at Millennium, Mr. Grmusa directly engaged with R&D leaders and the Millennium management team on pipeline investment management and strategic corporate planning. Prior to Millennium, he spent 3 years in consulting with Boston Biomedical Consultants.

Mr. Grmusa holds an MA in International Economics and Finance from Brandeis University and a BS in Finance from West Virginia University.